<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135313</url>
  </required_header>
  <id_info>
    <org_study_id>RuCorT-03</org_study_id>
    <nct_id>NCT04135313</nct_id>
  </id_info>
  <brief_title>Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer</brief_title>
  <acronym>RuCorT-03</acronym>
  <official_title>Induction and Consolidation Chemotherapy in Locally Advanced Rectal Cancer Patients With Circumferential Resection Margin Involvement: a Multicenter Prospective Randomized Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of 2 cycles of induction CapOx
      chemotherapy and 2 cycles of consolidation CapOx chemotherapy to standard chemoradiation
      improves 3-year disease-free survival in patients with locally advanced CRM&quot;+&quot; mid and low
      rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to investigate the efficacy of adding neoadjuvant induction and consolidation
      chemotherapy compared to standard chemoradiotherapy in locally advanced rectal cancer
      patients with circumferential resection margin involvement. This is a prospective multicenter
      open-label randomized phase III clinical trial. Patients will be randomized using an online
      randomization system to receive either 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv
      day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by
      chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid
      on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks
      following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy OR chemoradiotherapy
      (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation
      days), surgery (10-12 weeks following chemoradiotherapy) and 6 cycles of adjuvant CapOx
      chemotherapy. A stratification will be performed based on N stage, tumor location in the
      middle or low rectum and clinical center. Patients with middle or low rectal cancer without
      distant metastases, with involved circumferential resection margin (based on pretreatment
      MRI) will be included.

      The target accrual is 270 patients in each treatment arm (including 10% potential data loss)
      based on potential benefit of 12% 3-yr disease-free survival (60% vs 72%), α=0,05, power 80%
      in the experimental arm. An interim analysis is planned after 50% of the patients will reach
      a 3-year followup. Pelvic Magnetic Resonance Imaging (MRI) is performed in all patients for
      staging before and after neoadjuvant chemotherapy and before surgery. Pelvic MRI is subject
      to central review. Conduction of this study and data collection are controlled by a local
      institutional board.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 20, 2019</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjuvant chemotherapy compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who receive a complete course of adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute chemotherapy toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity measured according to NCI-CTCAE v.5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate (pCR)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Morbidity measured according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative tumor-associated complications rate</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of tumor-associated complications (bowel obstruction, bleeding etc) during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphincter preservation rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Rectal Neoplasms Malignant</condition>
  <condition>Rectum Carcinoma</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherpy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2, bid, per os, days 1-14</description>
    <arm_group_label>Chemoradiotherpy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2 iv day 1</description>
    <arm_group_label>Chemoradiotherpy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>Chemoradiotherpy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions</description>
    <arm_group_label>Chemoradiotherpy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal cancer surgery</intervention_name>
    <description>Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection</description>
    <arm_group_label>Chemoradiotherpy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Histologically verified colon rectal adenocarcinoma 0-10 cm above the anal verge

          -  No distant metastases

          -  Circumferential resection margin (CRM) involvement (based on pelvic MRI)

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

          -  Haemoglobin (HGB) &gt; 90 g/L

          -  Platelet Count (PLT) &gt; 120x10*9/L

          -  Serum creatinine &lt; 150 µmol/L

          -  Total bilirubin &lt; 25 µmol/L

        Exclusion Criteria:

          -  inability to obtain informed consent

          -  distant metastases

          -  cT2N0M0 rectal cancer

          -  synchronous or metachronous tumors

          -  previous chemotherapy or radiotherapy

          -  clinically significant cardiovascular disorders (myocardial infarction &lt; 6 months
             before visit, stroke &lt; &lt; 6 months before visit, instable angina &lt; 3 months before
             visit, arrhythmia, uncontrolled hypertension &gt; 160/100 mm hg

          -  clinically significant neurological disorders

          -  previous neuropathy 2 or higher

          -  current infection or heavy systemic disease

          -  pregnancy, breastfeeding

          -  ulcerative colitis

          -  individual intolerance to treatment components

          -  proven dihydropyrimidine dehydrogenase (DPD) deficiency

          -  participation in other clinical trials

          -  psychiatric disorders, which render patient unable to follow instructions or
             understand his/her condition

          -  technical inability to perform pelvic MRI

          -  inability of long-term followup of the patient

          -  HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaman Z Mamedli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N.Blokhin Russian Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>N.N.Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 20, 2019</study_first_submitted>
  <study_first_submitted_qc>October 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blokhin's Russian Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Sergey Gordeyev</investigator_full_name>
    <investigator_title>Principal Investigator, Consultant surgeon</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>consolidation chemotherapy</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

